Literature DB >> 19836628

Costs of the in-home patients affected by dementia.

G Isaia1, G Nobili, G Cappa, S Mondino, S Pilon, M Massaia.   

Abstract

In 2000, Alzheimer's disease (AD) and other dementias were the third most expensive health conditions in the USA and in 2005 their annual costs amounted to more than $148 billion. An observational, non-randomized study aimed to evaluate direct costs of demented patients in their homes. Two hundred thirty-six informal caregivers have been enrolled. A financial support, represented by a disability living allowance (15.3%) or attendance allowance (3.4%), was presented in just 19.7% of the cases. Patients receiving assistance from an employed carer were 39% with a mean cost of 800 Euro/month. Receiving assistance from an employed carer is not correlated with cognitive and functional impairment, with the age of the caregiver and with the duration of the disease (t=1.03; t=-0.86; t=1.41; t=-0.16, respectively). The informal caregivers declared that they thoughts about the possibility of institutionalize the patient were 20.9%. The present study underlines the discrepancy between subjects having assistance from an employed caregiver and subjects receiving financial supports. It often happens that patients not reaching the minimum requisites for social assistant or financial support, need at least a supervision.

Entities:  

Mesh:

Year:  2009        PMID: 19836628     DOI: 10.1016/j.archger.2009.09.024

Source DB:  PubMed          Journal:  Arch Gerontol Geriatr        ISSN: 0167-4943            Impact factor:   3.250


  2 in total

1.  Health economics and health policy issues in Alzheimer's disease.

Authors:  T Rapp
Journal:  J Nutr Health Aging       Date:  2010-10       Impact factor: 4.075

2.  Meta-analysis of population-based studies comparing risk of cerebrovascular accident associated with first- and second-generation antipsychotic prescribing in dementia.

Authors:  Ahsan Rao; Amna Suliman; Giles Story; Sabine Vuik; Paul Aylin; Ara Darzi
Journal:  Int J Methods Psychiatr Res       Date:  2016-04-27       Impact factor: 4.035

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.